Fred Hutch Cancer Center

What it reported doing in 2024

Research program: fred hutch researchers have advanced human understanding across a wide range of areas, reflecting the breadth and depth of expertise at fred hutch that allows us to develop potential cures for cancer and infectious diseases. Our teams also applied artificial intelligence and other novel approaches to match existing treatments to diagnoses or better understand how cancer may be impacting individuals in different ways. Fred hutch scientists are producing some of the most important breakthroughs in the prevention, early detection and treatment of cancer, HIV and other diseases. Our scientists study every aspect of the disease process to uncover factors that influence disease risk and progression. Fred hutch has been home to three nobel laureates, and our faculty includes more than 400 renowned researchers who collaborate with colleagues across the globe and mentor the next generation of scientific innovators. Our scientists conduct research on and develop therapies for many cancers - including blood cancers and solid tumors - as well as for HIV and other nonmalignant diseases. They study the disease process from every angle, from the most basic molecular and cellular levels to the population level. Their goals are to uncover the factors that influence a person's likelihood of developing and surviving a disease and use this knowledge to reduce risk, save lives and improve quality of life. Fred hutch researchers are experts in understanding the development of blood and solid tumor cancers as well as identifying new ways to diagnose, prevent and treat cancers. Their research includes a wide area of topics that affect cancer and infectious diseases such as behavioral research, cell and gene therapy, data science, disease prevention, health economics, virology, and more. In fy25, fred hutch researchers published 1,284 research articles and 44 patents were granted to fred hutch. Fred hutch research programs integrate the latest in computational, laboratory and patient-oriented clinical research methods to better understand the mechanisms that drive cancer and other human diseases. Our researchers are continually developing new therapeutic approaches and they develop and lead clinical trials that help move laboratory discoveries into new treatment options for patients. Our discoveries, which include proving that bone marrow transplantation can cure leukemias and other blood cancers, have saved more than a million lives worldwide.

Financial Efficiency

• Mission deployment rate: 86.5%; rating input score 87
• Program expense ratio: 87.4%; rating input score 87
• Fundraising efficiency: $24.37 raised per $1 spent on fundraising; rating input score 62; 62nd percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
• Pay-setting controls: 6 of 6 controls in place; rating input score 100
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Pass
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 3 of 8 controls in place; rating input score 38
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Limited
  • Conducts field audits: Limited
  • May suspend future funding: Limited
  • Requires financial reports: Limited
  • Conducts site visits: Pass
  • Requires grant agreements: Pass
  • May require repayment: Limited
• Grant itemization coverage: 99.9%; rating input score 100; 47th percentile among comparable filings
• Major donor itemization: Limited
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 88.2%; rating input score 88; 35th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 5%; rating input score 57; 57th percentile among comparable filings
• Total-asset coverage ratio: 1.5; rating input score 53; 53rd percentile among comparable filings
• Liabilities to assets ratio: 0.56; rating input score 31; 31st percentile among comparable filings
• Officer compensation ratio: 1%; rating input score 74; 74th percentile among comparable filings

Growth

• Program expense growth: 18.2% per year; rating input score 100; 91st percentile among comparable filings
• Revenue growth: 14.6% per year; rating input score 100; 88th percentile among comparable filings
• Asset growth: 17.2% per year; rating input score 100; 90th percentile among comparable filings